LifeMD outlines $250M+ annualized revenue run rate target by Q4 2026 on record GLP-1 demand
LifeMD beats Q4 2025 EPS and revenue estimates with non-GAAP EPS $0.41 and revenue $46.9M
- Q4 2025 non-GAAP EPS was $0.41, up 2150% YoY, on revenue $46.9M, down 27% YoY
- Q4 2025 adjusted EBITDA was $4.8 million, alongside revenue of $46.9 million
- Full-year 2025 revenue totaled $194.1M with adjusted EBITDA of $15.3M
- Company issued 2026 guidance for $220–230M revenue and $12–17M adjusted EBITDA
- Company highlighted the recent launch of oral Wegovy as part of its growth initiatives
- Year-end 2025 cash balance totaled $36.8 million, and the company reported no debt outstanding
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.